145020

Hugel is a biopharmaceutical company that researches, develops, manufactures, and sells medical aesthetic products. Its core business involves botulinum toxin type A, marketed under the brand Botulax (Letybo), and hyaluronic acid (HA) dermal fillers, sold as The Chaeum (Persnica). The company also offers skin boosters under the brand Byrezen, absorbable sutures for facial lifting under the Blue Rose brand, and dermocosmetics under the Wellage and Byrezen BR brands. Hugel serves healthcare professionals and consumers in the United States, Europe, China, and markets in Southeast Asia, Oceania, and Latin America. The company operates through internal sales and marketing divisions and subsidiaries, including Hugel America, Inc., Hugel Australia PTY LTD, and HUGEL Shanghai Aesthetics. A key subsidiary, Acros, focuses on the R&D and manufacturing of HA fillers, while Jayworld, acquired in 2020, handles the production of absorbable sutures. Hugel was founded in 2001 and has established partnerships with local distributors and pharmaceutical companies in various regions to facilitate market entry and distribution.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage hugel-inc.com
Sector Healthcare IR page hugel-inc.com
Tags
botulinum toxin, hyaluronic acid fillers, skin boosters, absorbable sutures, dermocosmetics, medical aesthetics, aesthetic injectables, facial lifting, anti-aging, Botulax, Letybo, The Chaeum, Persnica, Byrezen, Blue Rose, Wellage, Byrezen BR, Hugel America Inc., Hugel Australia PTY LTD, HUGEL Shanghai Aesthetics, Acros, Jayworld, Hugel Pharma
Press page hugel-inc.com/kr/media/news

Metrics

Valuation  
Market cap $ 3.002T
Market cap (USD) $ 2.21B
P/E 16.63
PEG 0.48
P/BV 2.85
P/S 6.26
P/OCF 16.55
P/FCF 20.24
Dividend yield —
Turnover / mcap —
Returns  
ROE 16.1%
ROI 14.8%
ROIC 15.8%
Profit margin 33.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 34.9%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock —
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 50.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 425.11B 373.047B 319.7B 281.675B 231.859B 211.038B 204.568B 182.392B 182.085B 124.189B 65.066B 40.35B 29.17B
Net profit 140.872B 135.814B 93.076B 57.332B 57.73B 41.992B 44.612B 69.736B 72.827B 50.901B 33.929B 13.15B 7.307B
Free cash flow 136.664B 136.697B 93.988B 47.803B 62.061B 57.325B 64.711B 56.694B 57.848B 29.519B 7.395B 4.694B -10.386B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 222.5K — — — — — — — — — — — —
P/FCF 20.03 — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 31.2B 62.8B 55.4B 37.5B 28B 28.4B 53.2B 44.1B 48.4B 75B
↳ YoY growth +51.8% +101.0% -11.8% -32.4% -25.3% +1.6% +87.0% -17.0% +9.6% +55.0%
↳ 5y CAGR +36.8% +14.3% +6.4% -1.9% -3.3% -4.4% +5.3% +21.8%
Borrowings, current (KRW) 300M — — 200M — — 97.8B 0.00 0.00 25.7B
Borrowings, non-current (KRW) — 79.6B 82.9B 86.4B 90.1B — — 88.8B — —
Bonds payable (KRW) — 79.6B 82.9B 86.4B 90.1B — 97.8B 88.8B 0.00 25.7B
Cash and deposits (KRW) 64.9B 31.3B 29B 15.3B 62.4B 294B 132B 106B 130B 210B
Intangible assets (KRW) 63.9B 63.7B 112B 134B 170B 197B 200B 182B 196B 191B
Net debt (borrowings + leases - cash) (KRW) -64.6B 48.3B 53.9B 71.3B 27.7B — -34B -17.2B -130B -184B
Cash flow detail
Operating cash flow (KRW) 45.1B 64.2B 65.8B 77B 74.3B 85.9B 80.6B 118B 149B 150B
Purchases of property, plant and equipment (KRW) -15.6B -6.34B -9.1B -12.3B -17B -23.9B -32.8B -23.7B -12.4B -13.4B
Purchases of intangible assets (KRW) -469M -884M -7.62B -16.1B -28.2B -24.5B -12.2B -16.8B -21B -16.1B
Dividends paid (cash effect) (KRW) — — — — — — 0.00 -106M 0.00 0.00
Share buybacks (cash effect) (KRW) -5.97B -2.09M -41.3B -46.2B — -36B -44.5B -122B -172B -1.32B
Interest paid (cash effect) (KRW) — — — -1.79B -116M -87M -99.4M -55.1M -547M -518M
Income taxes paid (cash effect) (KRW) -3.5B -17.2B -16B -14.2B -27.9B -26.9B -20.5B -37.2B -39B -47.8B
Free cash flow (OCF - PPE - intangibles) (KRW) 29B 57B 49.1B 48.6B 29.1B 37.5B 35.6B 77.2B 116B 121B
Income detail
Total comprehensive income (KRW) 50.9B 81.2B 72.8B 47B 48.9B 69.8B 63.4B 97.9B 161B 150B
Comprehensive income to owners (KRW) 43.3B 72.7B 67.7B 40.1B 47.3B 64.8B 58.1B 92.3B 153B 144B
Reported Jul 2, 2018 Jul 2, 2018 Apr 1, 2019 Mar 30, 2020 Mar 18, 2021 Mar 21, 2024 Mar 21, 2025 Mar 21, 2025 Mar 21, 2025 Mar 20, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

풍문또는보도에대한해명(미확정) Bull 0 Bear 0 Routine
기업설명회(IR)개최 Bull 0 Bear 0 Routine
주식소각결정 Bull 1 Bear 0 Capital return

Prompts

Hugel (ticker 145020), listed in South Korea.

ETFs Holding Hugel

ETF Weight in ETF Shares Market value As of
MEMS 3.14% 4,164 $ 709.544K Jun 30, 2026
MEMX 0.68% 1,994 $ 339.777K Jun 30, 2026
AVEE 0.08% 729 $ 103.968K Nov 16, 2026
DFSE 0.01% 560 $ 82.667K Nov 12, 2026
DFEM 0.01% 7,281 $ 1.075M Nov 12, 2026
DEXC 0.01% 184 $ 27.162K Nov 12, 2026
AVEM 0.01% 12,247 $ 1.747M Nov 16, 2026
AVXC 0.01% 186 $ 26.527K Nov 16, 2026
DFAE 0.01% 3,733 $ 551.063K Nov 12, 2026
DFAX 0.00% 3,720 $ 549.144K Nov 12, 2026
AVSE 0.00% 52 $ 7,416.08 Nov 16, 2026